CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction ...

SUNNYVALE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

“Dr. Quyyumi's significant expertise in these trials and inspiring leadership, coupled with the world-class capabilities at Emory University School of Medicine, a leading institution in the ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

For the third straight year, the U.S. News & World Report (USNWR) ranked Emory University’s Nell Hodgson Woodruff School of Nursing master’s program as No. 1. On April 8, USNWR released its rankings ...

BioCardia, Inc. [Nasdaq: BCDA], a company specializing in cellular therapies for cardiovascular and pulmonary diseases, announced that Emory University School of Medicine has begun enrolling ...

The trial is assessing the therapy for individuals with ischemic heart failure of minimised ejection fraction.

A newly published study by researchers from Emory University, the University of North ... of the Epidemiology Ph.D. program at the Rollins School of Public Health. "We are seeing that once ...

"It ticks all the boxes of everything we've been looking for," says Avtar Roopra, a neuroscience professor in the UW–Madison School of Medicine ... at Tufts University and Emory University ...

She also teaches medical trainees and lectures medical students at the Emory University School of Medicine. In her free time, Dr. Scott appreciates a good coffee shop, weekend hikes, playing ...